Products
Platform
Research
Market
Learn
IPO
Compare Nippon India Pharma Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.81 | 1.86 |
NAV | ₹515.20 | ₹40.21 |
Fund Started | 10 May 2004 | 25 Jun 2018 |
Fund Size | ₹8346.49 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.81
1.86
NAV
₹515.20
₹40.21
Fund Started
10 May 2004
25 Jun 2018
Fund Size
₹8346.49 Cr
₹6437.36 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | -0.53% | 3.16% |
3 Year | 20.97% | 26.63% |
5 Year | 16.10% | 18.60% |
1 Year
-0.53%
3.16%
3 Year
20.97%
26.63%
5 Year
16.10%
18.60%
Holding Analysis
Equity | 99.67% | 97.10% |
Cash | 0.33% | 2.90% |
Equity
99.67%
97.10%
Cash
0.33%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.67% |
Divi's Laboratories Ltd. | 8.07% |
Lupin Ltd. | 7.26% |
Cipla Ltd. | 6.29% |
Apollo Hospitals Enterprise Ltd. | 5.97% |
Dr. Reddy's Laboratories Ltd. | 5.62% |
Vijaya Diagnostic Centre Ltd. | 3.42% |
Medplus Health Services Ltd. | 3.32% |
Gland Pharma Ltd. | 3.05% |
Glaxosmithkline Pharmaceuticals Ltd. | 2.87% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Akshay Sharma | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Akshay Sharma
Dharmesh Kakkad
Start Date
01 Dec 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 10 May 2004 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
10 May 2004
25 Jun 2018